{"data":[{"accessionNo":"0001193125-26-399480","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001549595","issuerName":"Nurix Therapeutics, Inc.","ticker":"NRIX","cusip":"67080M103","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-09-16","reportingPerson":"Joseph Edelman","reportingCik":null,"personType":"IN","sharesOwned":5536629,"percentOfClass":5.3,"filedAt":"2026-09-23","canonicalUrl":"https://xoomar.com/markets/stocks/nrix"},{"accessionNo":"0001193125-26-399480","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001549595","issuerName":"Nurix Therapeutics, Inc.","ticker":"NRIX","cusip":"67080M103","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-09-16","reportingPerson":"Perceptive Advisors LLC","reportingCik":null,"personType":"IA","sharesOwned":5536629,"percentOfClass":5.3,"filedAt":"2026-09-23","canonicalUrl":"https://xoomar.com/markets/stocks/nrix"},{"accessionNo":"0001193125-26-399480","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001549595","issuerName":"Nurix Therapeutics, Inc.","ticker":"NRIX","cusip":"67080M103","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-09-16","reportingPerson":"Perceptive Life Sciences Master Fund, Ltd.","reportingCik":null,"personType":"CO","sharesOwned":5536629,"percentOfClass":5.3,"filedAt":"2026-09-23","canonicalUrl":"https://xoomar.com/markets/stocks/nrix"},{"accessionNo":"0001104659-26-097194","formType":"SCHEDULE 13G/A","amendmentNo":6,"issuerCik":"0001549595","issuerName":"Nurix Therapeutics, Inc.","ticker":"NRIX","cusip":"67080M103","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-06-30","reportingPerson":"Jeremy C. Green","reportingCik":null,"personType":"HC,IN","sharesOwned":8782256,"percentOfClass":8.1,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/nrix"},{"accessionNo":"0001104659-26-097194","formType":"SCHEDULE 13G/A","amendmentNo":6,"issuerCik":"0001549595","issuerName":"Nurix Therapeutics, Inc.","ticker":"NRIX","cusip":"67080M103","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-06-30","reportingPerson":"Redmile Group, LLC","reportingCik":null,"personType":"IA,OO","sharesOwned":8782256,"percentOfClass":8.1,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/nrix"},{"accessionNo":"0000902664-26-003499","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001549595","issuerName":"Nurix Therapeutics, Inc.","ticker":"NRIX","cusip":"67080M103","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-06-30","reportingPerson":"Ryan Wilder","reportingCik":null,"personType":"HC,IN","sharesOwned":8050000,"percentOfClass":7.8,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/nrix"},{"accessionNo":"0000902664-26-003499","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001549595","issuerName":"Nurix Therapeutics, Inc.","ticker":"NRIX","cusip":"67080M103","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-06-30","reportingPerson":"Vestal Point Capital, LP","reportingCik":null,"personType":"IA,PN","sharesOwned":8050000,"percentOfClass":7.8,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/nrix"},{"accessionNo":"0001172661-26-003488","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001549595","issuerName":"Nurix Therapeutics, Inc.","ticker":"NRIX","cusip":"67080M103","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-06-30","reportingPerson":"Deep Track Biotechnology Master Fund, Ltd.","reportingCik":null,"personType":"CO","sharesOwned":7736455,"percentOfClass":7.45,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/nrix"},{"accessionNo":"0001172661-26-003488","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001549595","issuerName":"Nurix Therapeutics, Inc.","ticker":"NRIX","cusip":"67080M103","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-06-30","reportingPerson":"Deep Track Capital, LP","reportingCik":null,"personType":"IA,OO","sharesOwned":7736455,"percentOfClass":7.45,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/nrix"},{"accessionNo":"0001172661-26-003488","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001549595","issuerName":"Nurix Therapeutics, Inc.","ticker":"NRIX","cusip":"67080M103","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-06-30","reportingPerson":"David Kroin","reportingCik":null,"personType":"HC,IN","sharesOwned":7736455,"percentOfClass":7.45,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/nrix"},{"accessionNo":"0001104659-26-097100","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001549595","issuerName":"Nurix Therapeutics, Inc.","ticker":"NRIX","cusip":"67080M103","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-06-30","reportingPerson":"David Rosen","reportingCik":null,"personType":"HC,IN","sharesOwned":7227778,"percentOfClass":6.96,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/nrix"},{"accessionNo":"0001104659-26-097100","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001549595","issuerName":"Nurix Therapeutics, Inc.","ticker":"NRIX","cusip":"67080M103","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-06-30","reportingPerson":"Rubric Capital Management LP","reportingCik":null,"personType":"IA,PN","sharesOwned":7227778,"percentOfClass":6.96,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/nrix"},{"accessionNo":"0000080255-26-000570","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001549595","issuerName":"NURIX THERAPEUTICS INC","ticker":"NRIX","cusip":"67080M103","securityClass":"COMMON STOCK","eventDate":"2026-06-30","reportingPerson":"T. Rowe Price Associates, Inc.","reportingCik":null,"personType":"IA","sharesOwned":5436587,"percentOfClass":5.3,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/nrix"},{"accessionNo":"0001104659-26-097194","formType":"SCHEDULE 13G/A","amendmentNo":6,"issuerCik":"0001549595","issuerName":"Nurix Therapeutics, Inc.","ticker":"NRIX","cusip":"67080M103","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-06-30","reportingPerson":"RedCo II Offshore SPV LLC","reportingCik":null,"personType":"FI,OO","sharesOwned":3712546,"percentOfClass":3.5,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/nrix"},{"accessionNo":"0002100119-26-001437","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001549595","issuerName":"Nurix Therapeutics Inc","ticker":"NRIX","cusip":"67080M103","securityClass":"Common Stock","eventDate":"2026-06-30","reportingPerson":"Vanguard Capital Management","reportingCik":null,"personType":"IA","sharesOwned":5202025,"percentOfClass":5.03,"filedAt":"2026-07-31","canonicalUrl":"https://xoomar.com/markets/stocks/nrix"},{"accessionNo":"0000902664-26-002545","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001549595","issuerName":"Nurix Therapeutics, Inc.","ticker":"NRIX","cusip":"67080M103","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"Ryan Wilder","reportingCik":null,"personType":"HC,IN","sharesOwned":6500000,"percentOfClass":6.3,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/nrix"},{"accessionNo":"0000902664-26-002545","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001549595","issuerName":"Nurix Therapeutics, Inc.","ticker":"NRIX","cusip":"67080M103","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"Vestal Point Capital, LP","reportingCik":null,"personType":"IA,PN","sharesOwned":6500000,"percentOfClass":6.3,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/nrix"},{"accessionNo":"0001172661-26-002030","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001549595","issuerName":"Nurix Therapeutics, Inc.","ticker":"NRIX","cusip":"67080M103","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"Deep Track Capital, LP","reportingCik":null,"personType":"IA,OO","sharesOwned":6345244,"percentOfClass":6.17,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/nrix"},{"accessionNo":"0001172661-26-002030","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001549595","issuerName":"Nurix Therapeutics, Inc.","ticker":"NRIX","cusip":"67080M103","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"Deep Track Biotechnology Master Fund, Ltd.","reportingCik":null,"personType":"CO","sharesOwned":6345244,"percentOfClass":6.17,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/nrix"},{"accessionNo":"0001172661-26-002030","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001549595","issuerName":"Nurix Therapeutics, Inc.","ticker":"NRIX","cusip":"67080M103","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"David Kroin","reportingCik":null,"personType":"HC,IN","sharesOwned":6345244,"percentOfClass":6.17,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/nrix"},{"accessionNo":"0000315066-26-001264","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001549595","issuerName":"NURIX THERAPEUTICS INC","ticker":"NRIX","cusip":"67080M103","securityClass":"COMMON STOCK","eventDate":"2026-03-31","reportingPerson":"FMR LLC","reportingCik":null,"personType":"HC","sharesOwned":5541271.11,"percentOfClass":5.4,"filedAt":"2026-05-06","canonicalUrl":"https://xoomar.com/markets/stocks/nrix"},{"accessionNo":"0000315066-26-001264","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001549595","issuerName":"NURIX THERAPEUTICS INC","ticker":"NRIX","cusip":"67080M103","securityClass":"COMMON STOCK","eventDate":"2026-03-31","reportingPerson":"Abigail P. Johnson","reportingCik":null,"personType":"IN","sharesOwned":5541271.11,"percentOfClass":5.4,"filedAt":"2026-05-06","canonicalUrl":"https://xoomar.com/markets/stocks/nrix"},{"accessionNo":"0001104659-26-048801","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001549595","issuerName":"Nurix Therapeutics, Inc.","ticker":"NRIX","cusip":"67080M103","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-04-20","reportingPerson":"Redmile Group, LLC","reportingCik":null,"personType":"IA,OO","sharesOwned":10696314,"percentOfClass":9.9,"filedAt":"2026-04-24","canonicalUrl":"https://xoomar.com/markets/stocks/nrix"},{"accessionNo":"0001104659-26-048801","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001549595","issuerName":"Nurix Therapeutics, Inc.","ticker":"NRIX","cusip":"67080M103","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-04-20","reportingPerson":"Jeremy C. Green","reportingCik":null,"personType":"HC,IN","sharesOwned":10696314,"percentOfClass":9.9,"filedAt":"2026-04-24","canonicalUrl":"https://xoomar.com/markets/stocks/nrix"},{"accessionNo":"0001104659-26-048801","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001549595","issuerName":"Nurix Therapeutics, Inc.","ticker":"NRIX","cusip":"67080M103","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-04-20","reportingPerson":"RedCo II Offshore SPV LLC","reportingCik":null,"personType":"FI,OO","sharesOwned":5967424,"percentOfClass":5.6,"filedAt":"2026-04-24","canonicalUrl":"https://xoomar.com/markets/stocks/nrix"},{"accessionNo":"0001104659-26-048801","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001549595","issuerName":"Nurix Therapeutics, Inc.","ticker":"NRIX","cusip":"67080M103","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-04-20","reportingPerson":"RedCo II Master Fund, L.P.","reportingCik":null,"personType":"PN,FI","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-04-24","canonicalUrl":"https://xoomar.com/markets/stocks/nrix"},{"accessionNo":"0000102909-26-002007","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001549595","issuerName":"Nurix Therapeutics Inc","ticker":"NRIX","cusip":"67080M103","securityClass":"Common Stock","eventDate":"2026-03-13","reportingPerson":"The Vanguard Group","reportingCik":null,"personType":"IA","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-03-27","canonicalUrl":"https://xoomar.com/markets/stocks/nrix"},{"accessionNo":"0001104659-26-016443","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001549595","issuerName":"Nurix Therapeutics, Inc.","ticker":"NRIX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"Baker Bros. Advisors LP","reportingCik":null,"personType":"IA,PN","sharesOwned":7527996,"percentOfClass":7.2,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/nrix"},{"accessionNo":"0001104659-26-016443","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001549595","issuerName":"Nurix Therapeutics, Inc.","ticker":"NRIX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"Baker Bros. Advisors (GP) LLC","reportingCik":null,"personType":"HC,OO","sharesOwned":7527996,"percentOfClass":7.2,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/nrix"},{"accessionNo":"0001104659-26-016443","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001549595","issuerName":"Nurix Therapeutics, Inc.","ticker":"NRIX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"Julian C. Baker","reportingCik":null,"personType":"HC,IN","sharesOwned":7527996,"percentOfClass":7.2,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/nrix"},{"accessionNo":"0001104659-26-016443","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001549595","issuerName":"Nurix Therapeutics, Inc.","ticker":"NRIX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"Felix J. Baker","reportingCik":null,"personType":"HC,IN","sharesOwned":7527996,"percentOfClass":7.2,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/nrix"},{"accessionNo":"0001831942-25-000030","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001549595","issuerName":"Nurix Therapeutics, Inc.","ticker":"NRIX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-09-30","reportingPerson":"Commodore Capital LP","reportingCik":null,"personType":"IA,PN","sharesOwned":3780055,"percentOfClass":4.9,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/nrix"},{"accessionNo":"0001831942-25-000030","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001549595","issuerName":"Nurix Therapeutics, Inc.","ticker":"NRIX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-09-30","reportingPerson":"Commodore Capital Master LP","reportingCik":null,"personType":"PN","sharesOwned":3780055,"percentOfClass":4.9,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/nrix"},{"accessionNo":"0000315066-25-002917","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001549595","issuerName":"NURIX THERAPEUTICS INC","ticker":"NRIX","cusip":null,"securityClass":"COMMON STOCK","eventDate":"2025-10-31","reportingPerson":"FMR LLC","reportingCik":null,"personType":"HC","sharesOwned":4159940.33,"percentOfClass":4.1,"filedAt":"2025-11-07","canonicalUrl":"https://xoomar.com/markets/stocks/nrix"},{"accessionNo":"0000315066-25-002917","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001549595","issuerName":"NURIX THERAPEUTICS INC","ticker":"NRIX","cusip":null,"securityClass":"COMMON STOCK","eventDate":"2025-10-31","reportingPerson":"Abigail P. Johnson","reportingCik":null,"personType":"IN","sharesOwned":4159940.33,"percentOfClass":4.1,"filedAt":"2025-11-07","canonicalUrl":"https://xoomar.com/markets/stocks/nrix"},{"accessionNo":"0000315066-25-002778","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001549595","issuerName":"NURIX THERAPEUTICS INC","ticker":"NRIX","cusip":null,"securityClass":"COMMON STOCK","eventDate":"2025-09-30","reportingPerson":"FMR LLC","reportingCik":null,"personType":"HC","sharesOwned":8787537.12,"percentOfClass":11.5,"filedAt":"2025-11-05","canonicalUrl":"https://xoomar.com/markets/stocks/nrix"},{"accessionNo":"0000315066-25-002778","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001549595","issuerName":"NURIX THERAPEUTICS INC","ticker":"NRIX","cusip":null,"securityClass":"COMMON STOCK","eventDate":"2025-09-30","reportingPerson":"Abigail P. Johnson","reportingCik":null,"personType":"IN","sharesOwned":8787537.12,"percentOfClass":11.5,"filedAt":"2025-11-05","canonicalUrl":"https://xoomar.com/markets/stocks/nrix"}],"updatedAt":"2026-10-24T14:40:26.645Z","source":"xoomar.com","docs":"https://xoomar.com/markets/api","license":"https://xoomar.com/terms","attribution":"Credit XOOMAR with a link to the dataset page on xoomar.com when you republish this data","canonicalUrl":"https://xoomar.com/markets/stocks/nrix","meta":{"source":"SEC","sourceAttribution":"Schedule 13D and 13G data: SEC.","notice":"10 requests a minute without a key, 30 with a free key. Get a free key at https://xoomar.com/signup?utm_source=api, register your app at https://xoomar.com/developers/register?utm_source=api, and credit the data as \"Data: XOOMAR\" together with the sourceAttribution line."}}